Edition:
United Kingdom

Qiagen NV (QGEN.N)

QGEN.N on New York Stock Exchange

34.17USD
20 Aug 2019
Change (% chg)

$-0.64 (-1.84%)
Prev Close
$34.81
Open
$34.53
Day's High
$34.53
Day's Low
$34.04
Volume
189,596
Avg. Vol
304,720
52-wk High
$41.52
52-wk Low
$32.36

Latest Key Developments (Source: Significant Developments)

Qiagen Affirms Q2 Results
Tuesday, 30 Jul 2019 

July 31 (Reuters) - Qiagen::Results remain unchanged from those announced July 24.Qiagen delivers on Q2 2019 outlook.Net sales of $381.6 million.Diluted EPS of $0.19.  Full Article

Qiagen's Says Now Expects Full-Year 2019 Net Sales Growth Of About 5-6% CER
Wednesday, 24 Jul 2019 

July 24 (Reuters) - Qiagen NV ::DGAP-ADHOC: QIAGEN N.V. QIAGEN'S RESULTS FOR SECOND QUARTER 2019 IN LINE WITH OUTLOOK AT CER, REVISED FULL-YEAR 2019 OUTLOOK DUE TO INTENDED RESTRUCTURING OF CHINA NGS PARTNERSHIP.QIAGEN NV SAYS QIAGEN NOW EXPECTS FULL-YEAR 2019 NET SALES GROWTH OF APPROXIMATELY 5-6% CER (PREVIOUSLY ABOUT 7-8% CER).QIAGEN NV SAYS NOW EXPECTS FY 2019 ADJUSTED DILUTED EPS OF APPROXIMATELY $1.42-1.44 CER PER SHARE (PREVIOUSLY ABOUT $1.45-1.47 CER).QIAGEN- CO INTENDS TO RESTRUCTURE CURRENT FORMAT OF ITS NGS PARTNERSHIP IN CHINA DUE TO SLOWER-THAN-EXPECTED UPTAKE OF INVITRO DIAGNOSTIC CLINICAL SEQUENCING.QIAGEN NV SAYS FOR Q3 OF 2019, QIAGEN EXPECTS NET SALES TO GROW APPROXIMATELY 4-5% CER.QIAGEN NV SAYS FOR Q3 OF 2019 ADJUSTED DILUTED EPS IS EXPECTED TO BE ABOUT $0.35-0.36 CER PER SHARE.  Full Article

Qiagen Qtrly Diluted EPS Of $0.13
Monday, 6 May 2019 

May 6 (Reuters) - Qiagen NV ::QIAGEN REPORTS RESULTS FOR FIRST QUARTER OF 2019 AND ANNOUNCES PLANS FOR NEW $100 MILLION SHARE REPURCHASE PROGRAM.QTRLY DILUTED EPS OF $0.13; ADJUSTED. EPS OF $0.27.NEW $100 MILLION SHARE REPURCHASE PROGRAM PLANNED.QTRLY NET SALES OF $348.7 MILLION, UP 1.5% ACTUAL.REAFFIRMS 2019 OUTLOOK FOR GROWTH IN NET SALES AND ADJUSTED EPS.Q1 EARNINGS PER SHARE VIEW $0.26, REVENUE VIEW $351.6 MILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $1.46, REVENUE VIEW $1.60 BILLION -- REFINITIV IBES DATA.  Full Article

Qiagen Acquires U.S. Molecular Decision Support N-Of-One Company
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Qiagen NV ::QIAGEN ACQUIRES N-OF-ONE, EXPANDING ITS CLINICAL BIOINFORMATICS CAPABILITIES IN MOLECULAR ONCOLOGY DECISION SUPPORT.ACQUIRE N-OF-ONE, INC., A PRIVATELY-HELD U.S. MOLECULAR DECISION SUPPORT COMPANY.N-OF-ONE'S TECHNOLOGY-ENABLED, YET HUMAN-DRIVEN, SERVICES AND PROPRIETARY MARKERMINE™ DATABASE ARE PLANNED TO BE INTEGRATED INTO QIAGEN CLINICAL INSIGHT (QCI).  Full Article

Qiagen Announces New Collaboration With Novartis
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Qiagen NV ::QIAGEN ANNOUNCES NEW COLLABORATION TO DEVELOP COMPANION DIAGNOSTIC TO GUIDE TREATMENT FOR PATIENTS WITH PIK3CA-MUTATED ADVANCED BREAST CANCER.QIAGEN - TO COLLABORATE WITH NOVARTIS TO DEVELOP COMPANION DIAGNOSTIC TO GUIDE TREATMENT FOR PATIENTS WITH PIK3CA-MUTATED ADVANCED BREAST CANCER.  Full Article

Blocktrade - Qiagen Bookrunner Says Deal Upsized To $500 Mln On Convertible Notes
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Qiagen's Bookrunner::BLOCKTRADE - QIAGEN: BOOKRUNNER SAYS DEAL UPSIZED TO $500M; BOOKS TO CLOSE AT 13.30 UK.  Full Article

Qiagen Convertible Notes Bookrunner Says Orders Below 1 Pct Coupon & 27.5 Pct Premium Risk Missing
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Qiagen's Bookrunner Says::BLOCKTRADE - QIAGEN: BOOKRUNNER SAYS ORDERS BELOW 1.00 PERCENT COUPON AND 27.5 PERCENT PREMIUM RISK MISSING; BOOKS CLOSE AT 12:30PM UKT.  Full Article

Qiagen Bookrunner Says Books Are Covered On Convertible Notes
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Qiagen NV's Bookrunner::BLOCKTRADE - QIAGEN: BOOKRUNNER SAYS BOOKS ARE COVERED, FURTHER GUIDANCE TO FOLLOW.  Full Article

Qiagen Announces Convertible Notes Offer
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Qiagen NV ::SAYS LAUNCHES NON-US OFFERING OF CASH SETTLED CONVERTIBLE NOTES COMBINED WITH CONVERTIBLE NOTE HEDGE AND WARRANT TRANSACTIONS.INTENDS TO PLACE NOTES IN AN AGGREGATE VOLUME OF $400 MILLION.NUMBER OF ORDINARY SHARES OF QIAGEN UNDERLYING NOTES WILL BE UP TO 8.5 MILLION, REPRESENTING APPROXIMATELY 3.8% OF CURRENT OUTSTANDING SHARES.INTENDS TO USE PROCEEDS FROM ISSUANCE OF NOTES FOR GENERAL CORPORATE PURPOSES.NOTES WILL HAVE A MATURITY OF 6 YEARS, WILL BE ISSUED AND REDEEMED AT 100% OF THEIR PRINCIPAL AMOUNT, PAY A COUPON BETWEEN 0.75% - 1.25% P. A..INITIAL CONVERSION PRICE WILL BE SET AT A CONVERSION PREMIUM OF 27.5%.  Full Article

Diasorin Launches New Liaison Quantiferon-TB Gold Plus In Partnership With Qiagen
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Diasorin Spa ::LAUNCHES NEW LIAISON QUANTIFERON-TB GOLD PLUS ASSAY AS AN AID FOR LATENT TUBERCULOSIS DETECTION IN PARTNERSHIP WITH QIAGEN.SAYS TEST WAS DEVELOPED IN A PARTNERSHIP BETWEEN DIASORIN AND QIAGEN.SAYS TEST WILL BE LAUNCHED IN U.S. BY 2019 AND IN CHINA BY 2020.  Full Article

German stocks - Factors to watch on July 25

BERLIN/FRANKFURT, July 25 The following are some of the factors that may move German stocks on Thursday: